Values for pulmonary blood volume and extravascular lung water (estimated as wet weight of lung tissue) were arrived at in intact, anesthetized rats by labelling of blood constituents with isotopes and rapidly freezing the whole animals in liquid nitrogen. On ventilating the animals with 10% O2 in N2/N2O, a reduction in lung blood content could be demonstrated. The degree of reduction depended on the type of anesthesia and ventilation used. In some animals the volume reduction was so marked that both arterial, venous and capillary blood compartments have most probably been involved. The water content of the lung tissue was also rapidly and markedly reduced during hypoxia. Increased plasma osmolarity in mixed venous blood could partly be responsible for this tissue water reduction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1748-1716.1977.tb05942.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Creatinine production rate is an integrative indicator to monitor muscle status in critically ill patients.
Crit Care
January 2025
Department of Anesthesiology and Critical Care Medicine, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Background: Both quantitative and qualitative aspects of muscle status significantly impact clinical outcomes in critically ill patients. Comprehensive monitoring of baseline muscle status and its changes is crucial for risk stratification and management optimization. However, repeatable and accessible indicators are lacking.
View Article and Find Full Text PDFFluorescence angiography with indocyanine green for low anterior resection in patients with rectal cancer: a prospective before and after study.
Tech Coloproctol
January 2025
Université Laval, 10, De l'Espinay St, Quebec City, QC, G1L 3L5, Canada.
Background: Inadequate bowel perfusion is among risk factors for colorectal anastomotic leaks. Perfusion can be assessed with indocyanine green fluorescence angiography (ICG) during colon resections. Possible benefits from its systematic use in high-risk patients with rectal cancer remain inconsistent.
View Article and Find Full Text PDFPropensity score matched cohort study on magnesium supplementation and mortality in critically ill patients with HFpEF.
Sci Rep
January 2025
Intensive Care Medicine, Heyou Hospital, Foshan, 528306, Guangdong, China.
Heart failure with preserved ejection fraction (HFpEF) emerges as a singular subclass of heart failure, bereft of specific therapeutic options. Magnesium, an indispensable trace element, is essential to the preservation of cardiac integrity. However, the association between magnesium supplementation and mortality in HFpEF patients remains unclear.
View Article and Find Full Text PDFA high fraction of inspired oxygen does not mitigate atelectasis-induced lung tissue hypoxia or injury in experimental acute respiratory distress syndrome.
Sci Rep
January 2025
Department of Pathology, Dokkyo Medical University School of Medicine and Graduate School of Medicine, 880 Kitakobayashi, Mibu, Shimotsugagun, Tochigi, 321-0293, Japan.
Although alveolar hyperoxia exacerbates lung injury, clinical studies have failed to demonstrate the beneficial effects of lowering the fraction of inspired oxygen (FO) in patients with acute respiratory distress syndrome (ARDS). Atelectasis, which is commonly observed in ARDS, not only leads to hypoxemia but also contributes to lung injury through hypoxia-induced alveolar tissue inflammation. Therefore, it is possible that excessively low FO may enhance hypoxia-induced inflammation in atelectasis, and raising FO to an appropriate level may be a reasonable strategy for its mitigation.
View Article and Find Full Text PDFFedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and "real-world" data.
Blood Cancer J
January 2025
School of Medicine, Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Fedratinib is a predominantly JAK2 inhibitor that has shown efficacy in untreated and ruxolitinib-exposed patients with myelofibrosis (MF). Based on randomized clinical trial data, it is approved for use in patients with International Prognostic Scoring System (IPSS) or Dynamic International Prognostic Scoring System (DIPSS) intermediate-2 or high-risk disease and is distinguished from ruxolitinib in that it can be administered without dose reduction in patients with thrombocytopenia, to a platelet count above 50,000/µL. In these trials, fedratinib achieved significant spleen volume reduction in ~30-45% of patients and improvement in total symptom scores in 35-40% with good tolerability.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!